N-ACETYL MANNOSAMMINE AS A THERAPEUTIC AGENT
The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.
1 . A method of treating a condition or disease in a mammal in need thereof comprising administering an effective amount of a sialic acid precursor, N-acetyl mannosamine or a derivative thereof, to the mammal, wherein the derivative consists of Formula I.
wherein R 1 , R 3 , R 4 , or R 5 is hydrogen, lower alkanoyl, carboxylate or lower alkyl; R 2 is lower alkyl, lower alkanoylalkyl, lower alkyl alkanoyloxy; and the condition or disease is selected from muscular atrophy, muscular dystrophy, high blood pressure, or diabetes.
2 . The method of claim 1 , comprising administering a therapeutic amount of N-acetyl mannosamine to the mammal.
3 . The method of claim 2 , wherein the therapeutic amount is about 0.1 g to about 50 g N-acetyl mannosamine per day.
4 . The method of claim 2 , wherein the therapeutic amount is administered in a unit dosage of about 0.01 g to about 50 g N-acetyl mannosamine per unit dosage.
5 . The method of claim 1 , comprising sustained release of the sialic acid precursor, N-acetyl mannosamine or a derivative thereof.
6 . The method of claim 1 , comprising topical administration of the sialic acid precursor, N-acetyl mannosamine or a derivative thereof.